DGM
Darwin Global Management Portfolio holdings
AUM
$2.38B
This Quarter Return
+27.09%
1 Year Return
+81.43%
3 Year Return
+6,053.69%
5 Year Return
–
10 Year Return
–
AUM
$655M
AUM Growth
+$655M
(+20%)
Cap. Flow
+$121M
Cap. Flow
% of AUM
18.52%
Top 10 Holdings %
Top 10 Hldgs %
98.53%
Holding
17
New
5
Increased
4
Reduced
4
Closed
4
Top Buys
| 1 |
Pfizer
PFE
|
$455M |
| 2 |
AstraZeneca
AZN
|
$29.8M |
| 3 |
Enanta Pharmaceuticals
ENTA
|
$12.4M |
| 4 |
Keros Therapeutics
KROS
|
$6.52M |
| 5 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$5.89M |
Top Sells
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$344M |
| 2 |
Intellia Therapeutics
NTLA
|
$17.3M |
| 3 |
BridgeBio Pharma
BBIO
|
$11.9M |
| 4 |
Fate Therapeutics
FATE
|
$11.7M |
| 5 |
BioNTech
BNTX
|
$11.1M |
Sector Composition
| 1 | Healthcare | 99.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pfizer
PFE
$141B
| $455M | 69.44% | +7,697,762 | New | +$455M |
|
|
2
Intellia Therapeutics
NTLA
$1.22B
| $71.6M | 10.94% | 605,587 -146,437 | -19% | -$17.3M |
|
|
3
AstraZeneca
AZN
$248B
| $29.8M | 4.56% | +511,908 | New | +$29.8M |
|
|
INBX
4
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $25.9M | 3.95% | 591,975 +49,389 | +9% | +$2.16M |
|
|
5
BioNTech
BNTX
$24B
| $23.2M | 3.55% | 90,057 -42,875 | -32% | -$11.1M |
|
|
6
Enanta Pharmaceuticals
ENTA
$180M
| $12.4M | 1.9% | +166,190 | New | +$12.4M |
|
|
7
Fate Therapeutics
FATE
$120M
| $8.98M | 1.37% | 153,537 -199,713 | -57% | -$11.7M |
|
|
8
Keros Therapeutics
KROS
$618M
| $6.52M | 1% | +111,500 | New | +$6.52M |
|
9
Vir Biotechnology
VIR
$686M
| $6.11M | 0.93% | 145,841 +100,530 | +222% | +$4.21M |
|
|
CCXI
10
DELISTED
ChemoCentryx, Inc.
CCXI
| $5.89M | 0.9% | +161,802 | New | +$5.89M |
|
11
Fulcrum Therapeutics
FULC
$351M
| $5.62M | 0.86% | 317,428 +283,431 | +834% | +$5.01M |
|
12
Aclaris Therapeutics
ACRS
$209M
| $3.14M | 0.48% | 216,143 +56,750 | +36% | +$825K |
|
|
VERV
13
DELISTED
Verve Therapeutics
VERV
| $852K | 0.13% | 23,104 -4,293 | -16% | -$158K |
|
|
JBIO
14
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| – | – | -12,484 | Closed | -$262K |
|
|
15
BridgeBio Pharma
BBIO
$9.89B
| – | – | -253,692 | Closed | -$11.9M |
|
16
Invivyd
IVVD
$204M
| – | – | -86,528 | Closed | -$3.66M |
|
|
XLRN
17
DELISTED
Acceleron Pharma Inc.
XLRN
| – | – | -2,000,000 | Closed | -$344M |
|